Physician profile
James D Kaplan
NPI 1225121601
$4,185.20
in general payments reported to CMS, 2019-2025
22 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2021: $43.09 · 2022: $185 · 2023: $2,025 · 2024: $430 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,551 · Food and Beverage: $1,359 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,550.97 |
| Food and Beverage | $1,358.82 |
| Education | $234.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $2,012.32 | 2023 | |
| Olympus Corporation of The Americas | $558.35 | 2019-2022 | |
| Intuitive Surgical, INC. | $255.13 | 2024-2025 | |
| Grifols USA, LLC | $230.19 | 2019-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $220.20 | 2022-2024 | Fasenra |
| Astellas Pharma US INC | $199.90 | 2025 | |
| Steris Corporation | $138.65 | 2025 | |
| Ucb, INC. | $113.67 | 2019 | |
| Insmed, INC. | $108.14 | 2024-2025 | Arikayce, Brinsupri |
| Ge Healthcare | $47.79 | 2019 | |
| Amgen INC. | $41.61 | 2024-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $41.16 | 2023-2025 | |
| Ethicon INC. | $39.76 | 2025 | Monarch Platform |
| Boston Scientific Corporation | $31.05 | 2021 | |
| Electromed, INC. | $26.43 | 2025 | Smartvest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $23.56 | 2025 | |
| Merck Sharp & Dohme LLC | $20.05 | 2025 | Zerbaxa |
| Biogen, INC. | $18.93 | 2025 | Vumerity, Tysabri |
| Medtronic, INC. | $17.65 | 2025 | Illumisite |
| Harmony Biosciences LLC | $14.48 | 2025 | |
| Genentech USA, INC. | $14.14 | 2022 | |
| Abbvie INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.